OptimizeRx Corp
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $109.4M | $92.1M | $71.5M | $62.5M | $61.3M |
| Gross profit | $73.6M | $59.4M | $42.9M | $39.0M | $35.6M |
| Operating income | $11.7M | -$13.7M | -$26.4M | -$12.3M | $361,100 |
| Operating expenses | $61.9M | $73.1M | $69.3M | $51.3M | $35.3M |
| Cost of revenue | $35.8M | $32.7M | $28.6M | $23.5M | $25.7M |
| Cash from operations | $18.7M | $4.9M | -$7.2M | $10.7M | $726,039 |
| Capital expenditure | $58,000 | $112,000 | $87,000 | $81,005 | $100,322 |
| Free cash flow | $18.7M | $4.8M | -$7.3M | $10.6M | $625,717 |
| Share repurchases | — | — | $7.5M | $20.0M | — |
| Impairments | $368,000 | $7.5M | $6.7M | — | — |
| Total assets | $176.9M | $171.2M | $183.4M | $134.7M | $141.0M |
| Total liabilities | $48.6M | $54.2M | $56.8M | $8.5M | $9.6M |
Shares outstanding 18.8M · Free float 67.1%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.